Loretta S. Li

Hematology | Oncology
225 E Chicago Ave
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells.

PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells.

Journal: Blood advances
Published: October 27, 2025

American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.

American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.

Journal: Blood advances
Published: October 06, 2025

ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.

ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.

Journal: Blood advances
Published: October 06, 2025

PRL2 Phosphatase Promotes Oncogenic KIT Signaling in Leukemia Cells through Modulating CBL Phosphorylation.

PRL2 Phosphatase Promotes Oncogenic KIT Signaling in Leukemia Cells through Modulating CBL Phosphorylation.

Journal: Molecular cancer research : MCR
Published: February 22, 2023

Multifocal bone marrow disease in a young female with myeloid sarcoma.

Multifocal bone marrow disease in a young female with myeloid sarcoma.

Journal: Pediatric blood & cancer
Published: December 24, 2022

PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371.

PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371.

Journal: Blood
Published: April 11, 2022

New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.

New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.

Journal: Cell chemical biology
Published: March 01, 2022

The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target.

The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target.

Journal: Oncogene
Published: December 21, 2021

Therapy-related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature.

Therapy-related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature.

Journal: Pediatric blood & cancer
Published: July 21, 2021

Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.

Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.

Journal: British journal of haematology
Published: January 12, 2018

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Journal: Cancer cell
Published: August 02, 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Journal: Cancer cell
Published: December 14, 2015
Showing 1-12 of 13

Last Updated: 09/26/2026